Trial Profile
A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Sirolimus
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms Sickle-AID
- 28 Nov 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2028.
- 28 Nov 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2028.
- 23 Mar 2020 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.